Premium
P4–385: Statin use protects against cognitive decline in African–American elderly
Author(s) -
Hendrie Hugh,
Shen Jianzhao John,
Gao Sujuan,
Unverzagt Fred W.,
Murrell Jill,
Hall Kathleen S.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.2126
Subject(s) - cognitive decline , dementia , medicine , cohort , cognition , apolipoprotein e , gerontology , cohort study , population , epidemiology , statin , effects of sleep deprivation on cognitive performance , demography , disease , psychiatry , environmental health , sociology
treatment and reasons for discontinuation in 125 patients (66 females) who were treated in our outpatient clinic between 2000 2004. From among 66 patients who had started treatment on donepezil, 30 discontinued (45%), 21due to apparent lack of efficacy, two due to side effects and seven due to other reasons. The mean duration of treatment was 35.7 20.3 months, median 34. The results of MMSE examinations at onset of the treatment were mean 20 4.3, median 22, and at discontinuation 13 4.9, median 11. 59 patients were started on rivastigmine, of whom 33 discontinued (56%), 14 due to apparent lack of efficacy, 11 due to side effects and eight due to other reasons. The mean duration of treatment was 27.7 18.8 months, median 26. The results of MMSE examination at onset of the treatment were mean 21 3.5, median 23, and at discontinuation 17 4.7, median 16. A two-tailed T-test for differences of duration of treatment between the 2 groups favored donepezil (p 0.041). Conclusions: Patients seem to be maintained longer on donepezil than on rivastigmine. Apparent lack of efficacy was the main reason for discontinuation of both. The efficacy of both treatments seems similar.